Zionexa has appointed a new Regulatory Affairs Manager to drive its regulatory strategy and ensure the application of pharmaceutical regulations for the development, registration and operation of products. Corinne Sulger joins Zionexa from MSD France.
Created in May 2018, Zionexa is an international company developing and commercializing Molecular Imaging Companion Diagnostics (CDx) for targeted therapies in Oncology aimed at improving patients’ pathway and quality of life. Zionexa is actively working on developing its pipeline of molecules and Corinne will support this thanks to her regulatory expertise, in order for Zionexa to commercialize new biomarkers in the U.S. and Europe.
Corinne Sulger joins the Zionexa’s Paris office with a 20-year experience in pharmaceutical regulatory affairs.
“I’m looking forward to discover another facet of the pharmaceutical industry and its industrial specificities. This new mission is important to me and matches perfectly my professional credo – patients first – “, Corinne Sulger said.
Prior joining Zionexa, Corinne Sulger worked 14 years with MSD France, where she was Regulatory Affairs Pharmacist, in charge of products registration in the diabetic and cardiometabolic areas. Prior to this, Corinne worked 4 years at G. Gam Laboratories, a Hexal’s subsidiary specialized in generic medicines production and distribution, as Deputy Director of Regulatory Affairs, as well as 3 years at Besins International Laboratories, as Regulatory Affairs Manager.
Commenting on Corinne’s new assignment at Zionexa, Jean-Bernard Deloye, Head of Market Access: “Corinne is an expert in her field and we are pleased to welcome her in the team. We are confident that she will be a key member for the success of our development projects.”